Antidepressant

PreclinicalSmall molecule

Johnson & Johnson

Antidepressant is one of 226 small molecule programs targeting Delirium. It is currently in Preclinical.

Indications

Total Trials

Active Trials

225

Competitors

Pipeline

Status by Indication[3][1]

Indication

DeliriumActive, not recruiting

Major Depressive DisorderActive, not recruiting

SchizophreniaActive, not recruiting

Bipolar DisorderActive, not recruiting

StrokeActive, not recruiting

PsychosisActive, not recruiting

DeliriumPreclinical

Active, not recruiting

Major Depressive DisorderPreclinical

Active, not recruiting

SchizophreniaPreclinical

Active, not recruiting

Bipolar DisorderPreclinical

Active, not recruiting

StrokePreclinical

Active, not recruiting

PsychosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

174 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Preclinical

1 2

Resotran

Takeda

Preclinical

1 3

Inapsine

Jazz Pharmaceuticals

Preclinical

1 4

Depakote

Ibrance

Lunesta

3 7

Luvox

SSolvay Pharmaceuticals

Preclinical

1 8

Catapres

Boehringer Ingelheim

Preclinical

1 9

Rapamune

PPrism Pharmaceuticals

Preclinical

1 10

Persantine

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Post-ApprovalNot yet recruiting

Transcranial Magnetic Stimulation

NCT06644833

Clinical

Trials by Indication[1]

Major Depressive Disorder2 trials

Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder

Completed·—··NCT05952713·73,336 enrolled

Early Improvement in Individual Symptoms and Response to Antidepressants in Patients With Major Depressive Disorder

Unknown status·UUniversity Medical Center Groningen··NCT02934035·10,000 enrolled

Depression2 trials

Research on the Biological Mechanism of the Efficacy of Psychotherapy for Depression Based on the fNIRS

Unknown status·FFirst Affiliated Hospital of Zhejiang University·N/A·NCT05927129·90 enrolled

Predictors of the Outcome of Late Life Depression

Unknown status·UUniversity of Sao Paulo General Hospital··NCT02441387·120 enrolled

Delirium1 trial

Association Between Prescription of Antidepressants and Delirium in the Elderly : Analysis From the World Health Organization Global Database

Unknown status·UUniversity Hospital, Caen··NCT05356078·10,000 enrolled

Treatment Resistant Depression1 trial

A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression

Withdrawn· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT05268497

Schizophrenia1 trial

Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia

Completed·NNew York State Psychiatric Institute··NCT02775864·81,921 enrolled

11 more indications

Stroke1 trial

Can Acupuncture Treat Post-stroke Depression?

Completed·TThe University of Hong Kong·N/A·NCT02644161·91 enrolled

Transcranial Magnetic Stimulation1 trial

Effective of Transcranial Magnetic Stimulation (TMS) vs Treatment as Usual for First-Episode Depression in Adults

Not yet recruiting·SSultan Qaboos University·Phase 4·NCT06644833·120 enrolled

Treatment1 trial

Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)

Unknown status·UUniversity Hospital Muenster··NCT05537558·300 enrolled

Neonatal1 trial

Neonatal Hypotonia Associated With in Utero Exposure to Antidepressant

Unknown status·UUniversity Hospital, Caen··NCT04830241·10,000 enrolled

Insomnia1 trial

TRIAD - Treatment of Insomnia and Depression

Completed·SStanford University·Phase 2/3·NCT00767624·150 enrolled

Imaging1 trial

Multimodal Imaging of ECT Effects

Completed·—··NCT02871141·68 enrolled

Psychosis1 trial

The Role of Antidepressants or Antipsychotics in Preventing Psychosis

Withdrawn·SSt. Luke's-Roosevelt Hospital Center·N/A·NCT01724372

Bipolar Disorder1 trial

Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder

Completed·WWestern University, Canada··NCT02970721·3,357 enrolled

Breast Cancer1 trial

Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00087399·118 enrolled

Major Depression1 trial

Eealy Improvement Predicts Antidepressants Response in Adults With Major Depression Disorder

Unknown status·HHuashan Hospital··NCT03230682·80 enrolled

Chronic Low Back Pain1 trial

Proof of Concept Study to Treat Negative Affect in Chronic Low Back Pain

Completed·AAjay Wasan, MD, Msc·Phase 2·NCT04747314·308 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Antidepressant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antidepressant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antidepressant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Johnson & Johnson

Antidepressant

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Major Depressive Disorder2 trials

Depression2 trials

Delirium1 trial

Treatment Resistant Depression1 trial

Schizophrenia1 trial

Stroke1 trial

Transcranial Magnetic Stimulation1 trial

Treatment1 trial

Neonatal1 trial

Insomnia1 trial

Imaging1 trial

Psychosis1 trial

Bipolar Disorder1 trial

Breast Cancer1 trial

Major Depression1 trial

Chronic Low Back Pain1 trial

References

Drug Info

Quick Facts

Related News